Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an AI eye guide surgeons to safer, faster cancer removal?

NCT ID NCT07757906

Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the participants will have the standard procedure, while the other half will use the AI guidance. The study measures whether the AI reduces surgery time and doctor fatigue, and whether it lowers risks like bleeding or damage to the esophageal wall.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based Dissection Trajectory Prediction System (ADTPS), a software that overlays a recommended cutting path on endoscopic images during surgery
What this could lead to
If it works, this AI guidance could make endoscopic removal of early esophageal cancer quicker, less tiring for surgeons, and possibly reduce complications like bleeding or perforation.
What could go wrong
This is a single-center trial with 160 patients, so results may not apply broadly. The AI only offers visual guidance, and its benefit over standard care is unproven; there is also a risk of technical failures or inaccurate predictions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chinese patients aged 18-80 years. Lesions meeting ESD indications for esophageal, gastric, or colorectal early cancer or high-grade intraepithelial neoplasia, as defined by: Non-invasive tumors regardless of size; or Differentiated-type intramucosal carcinoma without ulceration, regardless of size; or Differentiated-type intramucosal carcinoma with ulceration and a diameter ≤3 cm; or Undifferentiated-type intramucosal carcinoma without ulceration and a diameter ≤2 cm. Planned to undergo ESD treatment. No prior treatment for the lesion (including ESD, surgery, radiotherapy, chemotherapy, etc.). Platelet count \>100 × 10⁹/L and PT-INR \<1.5, with antiplatelet agents (aspirin, clopidogrel, etc.) discontinued for at least 5 days. American Society of Anesthesiologists (ASA) physical status grade I or II. Voluntarily signed informed consent. Exclusion Criteria: * Patients currently undergoing dialysis. Patients with severe cardiopulmonary disease or other severe comorbidities that may increase the risk of the ESD procedure. Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ai-based dissection trajectory prediction system are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma esophagus carcinoma in situ intraepithelial neoplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ai-based dissection trajectory prediction system Esophageal squamous cell carcinoma (ESCC) High-grade intraepithelial neoplasia

Contacts and locations

Locations

  • 山东大学齐鲁医院

    Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.